Drug Trial Radar · NCT01850524
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jul 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
705
Actual
Start
Apr 29, 2013
Primary completion
Dec 2, 2019
Study completion Jun 24, 2022
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- May 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Conditions
- Multiple Myeloma
Interventions
IxazomibDrug
IXAZOMIB capsules.
PlaceboDrug
IXAZOMIB matching-placebo capsules.
DexamethasoneDrug
Dexamethasone tablets.
LenalidomideDrug
Lenalidomide capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 79 months
Locations
147 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Chandler, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Corona, California
Site not named
Fountain Valley, California
Site not named
Fullerton, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
Mission Hills, California
Site not named
Oakland, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
San Jose, California
Site not named
San Leandro, California
Site not named
Santa Clara, California
Site not named
South San Francisco, California
Site not named
Vallejo, California
Site not named
Denver, Colorado
Site not named
Fort Collins, Colorado
Site not named
Hartford, Connecticut
Site not named
Plainville, Connecticut
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Marietta, Georgia
Site not named
Honolulu, Hawaii
Site not named
Iowa City, Iowa
Site not named
Sioux City, Iowa
Site not named
Louisville, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Baltimore, Maryland
Site not named
Towson, Maryland
Site not named
Burlington, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.